8-KLeadership ChangesExhibits & Filings

BIOGEN INC. 8-K Report, Executive Changes (Dec 19, 2016)

Filed December 19, 2016For Securities:BIIB

Summary

Biogen Inc. (BIIB) announced a significant leadership change on December 19, 2016, with the appointment of Michel Vounatsos as its new Chief Executive Officer, effective January 6, 2017. Mr. Vounatsos, who has been with Biogen since April 2016 as Executive Vice President and Chief Commercial Officer, will also join the Board of Directors. He succeeds George A. Scangos, who will step down from his CEO role and Board position. This transition marks a new chapter for Biogen under Vounatsos's leadership, bringing his extensive 20-year experience from Merck to guide the company. The filing details Mr. Vounatsos's employment agreement, outlining his compensation package, which includes a substantial base salary, annual bonus opportunities, and significant long-term equity awards for 2017. The agreement also specifies terms for termination, severance, and continued medical coverage, reflecting a comprehensive approach to executive transition.

Key Highlights

  • 1Michel Vounatsos appointed as Chief Executive Officer, effective January 6, 2017.
  • 2George A. Scangos will step down as CEO and from the Board of Directors.
  • 3Mr. Vounatsos, age 55, brings 20 years of experience from Merck, most recently as President, Primary Care.
  • 4Employment Agreement includes an initial annual base salary of $1,100,000.
  • 5Target annual bonus opportunity of not less than 125% of base salary.
  • 6In 2017, Mr. Vounatsos will receive long-term incentive awards valued at $10,000,000 (50% cash-settled performance shares, 50% market stock units).
  • 7Detailed severance and change-in-control provisions are outlined in the employment agreement, including significant payouts and extended medical benefits.

Frequently Asked Questions

Michel Vounatsos has been appointed as the new Chief Executive Officer of Biogen, effective January 6, 2017. George A. Scangos will be stepping down from his CEO role and his position on the Board of Directors.

Michel Vounatsos, age 55, joined Biogen in April 2016 as Executive Vice President and Chief Commercial Officer. Prior to Biogen, he spent 20 years at Merck, where he held various leadership positions, most recently serving as President, Primary Care.

Mr. Vounatsos's employment agreement includes an annual base salary of $1,100,000, a target annual bonus opportunity of at least 125% of his base salary, and significant long-term incentive awards in 2017 valued at $10,000,000, split between cash-settled performance shares and market stock units.

The employment agreement outlines specific provisions for termination. In the event of an 'Involuntary Employment Action' (termination without cause or constructive termination), Mr. Vounatsos is eligible for severance payments, continued medical coverage, and career transition services. These benefits are enhanced in the event of a Change in Control, including a larger severance multiplier and extended medical coverage.